• IMA sites
  • IMAJ services
  • IMA journals
  • Follow us
  • Alternate Text Alternate Text
עמוד בית
Sun, 14.07.24


IMAJ | volume 25

Journal 8, August 2023
pages: 573-574

Successful Therapy with Canakinumab and Mepolizumab for Familial Mediterranean Fever and Eosinophilic Pneumonia

1 Department of Pulmonology Medicine, Meir Medical Center, Kfar Saba, Israel 2 Department of Internal Medicine A, Meir Medical Center, Kfar Saba, Israel 3 Department of Rheumatology, Meir Medical Center, Kfar Saba, Israel 4 Division of Pulmonology Medicine, Barzilai University Medical Center, Ashkelon, Israel 5 Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 6 Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel


Biological therapies with monoclonal antibodies have revolutionized the management of many inflammatory and autoimmune diseases. Combining biological treatments is very rarely indicated and may theoretically result in severe adverse effects, specifically, an increased tendency toward infectious diseases. We present the case of a woman in whom combination therapy with canakinumab for familial Mediterranean fever (FMF) and mepolizumab for chronic eosinophilic pneumonia was successfully employed.

Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
© All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

2 Twin Towers, 35 Jabotinsky, POB 4292, Ramat Gan 5251108 Israel